A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
Terminated · Phase 4 · NCT03173092
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $74,500
- U.S. investigators named
- 13
- Sites paid
- 5
- Planned or actual enrollment
- 141
About the trial
- Sponsor
- Takeda
- Tested
- Ixazomib (drug), Lenalidomide (drug), Dexamethasone (drug)
- Dates
- Started 2017-11-13; completion 2026-03-30
- Results posted
- Not yet
The main aim is to evaluate the effect of Ixazomib in combination with lenalidomide and dexamethasone on Multiple Myeloma disease progression at 2 years in participants who previously received a bortezomib-based induction regimen. The study will enroll approximately 160 participants, who are enrolled after completing 3 cycles of chemotherapy (Bortezomib-Based Induction Regimen). They are then treated with Ixazomib in addition to lenalidomide and dexamethasone.
From ClinicalTrials.gov, last updated 2026-05-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $74,500 in research payments for this study in 2025 (36 payments).
Products named: Ninlaro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sudhir Manda, MD Hematology & Oncology · Tucson, AZ
- David J. Andorsky, MD Hematology & Oncology · Boulder, CO
- Robert M. Rifkin, MD Hematology & Oncology · Denver, CO
- Michael J. Poiesz, M.D. Medical Oncology · Pensacola, FL
- Nisha S. Joseph, M.D. Medical Oncology · Atlanta, GA
- Ruemu E. Birhiray, MD Hematology & Oncology · Indianapolis, IN
- Ramalingam Ratnasabapathy, MD Hematology & Oncology · Henderson, NV
- Saulius K. Girnius Hematology & Oncology · Montgomery, OH
- Christopher A. Yasenchak, M.D. Hematology & Oncology · Eugene, OR
- Murtaza N. Bhuriwala, MD Medical Oncology · Tomball, TX
- Roger M. Lyons, MD Hematology · San Antonio, TX
- Kristi J. Mcintyre, MD Medical Oncology · Dallas, TX
- Habte A. Yimer IV, M.D. Hematology & Oncology · Tyler, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- US Oncology Research LLC $54,355
- Emory University Hospital, GA $10,858
- Good Samaritan Hospital, OH $7,862
- Waldron Medical Research & Development LLC $945
- Investigative Clinical Research of Indiana LLC $480
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.